To read the full story, subscribe or sign in.

Xuanzhu Pharma acquires Combio in bid to expand biologics pipeline

Feb. 9, 2021

HONG KONG – Xuanzhu Biopharmaceutical Co. Ltd., a subsidiary of Beijing-based Sihuan Pharmaceutical Holdings Group Ltd., has acquired antibody technology firm Beijing Combio Pharmaceutical for an undisclosed amount.

BioWorld Asia Deals and M&A Bi-specific antibody China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for March 1.

Gloved hand places sample tubes in PCR system

COVID-19 test makers are adapting for variants

BioWorld MedTech

As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for March 1.

Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

BioWorld

HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...